Farther Finance Advisors’s Viridian Therapeutics VRDN Stock Holding History

Farther Finance Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.23K	Sell	338 -891	-72%	-$14.4K	﹤0.01%	4674
2026 Q1	$23.5K	Sell	1,229 -126	-9%	-$3.74K	﹤0.01%	3543
2025 Q4	$42.2K	Sell	1,355 -585	-30%	-$16K	﹤0.01%	2932
2025 Q3	$41.9K	Buy	1,940 +1,491	+332%	+$26.9K	﹤0.01%	2548
2025 Q2	$6.28K	Buy	449 +448	+44,800%	+$6.08K	﹤0.01%	3276
2025 Q1	$13	Hold	1	–	–	﹤0.01%	4212
2024 Q4	$19	Hold	1	–	–	﹤0.01%	3936
2024 Q3	$23	Hold	1	–	–	﹤0.01%	3917
2024 Q2	$13	Hold	1	–	–	﹤0.01%	3773
2024 Q1	$17	Hold	1	–	–	﹤0.01%	3541
2023 Q4	$22	Buy	+1	New	+$16	﹤0.01%	3453

Other funds holding VRDN

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return

Eleva Capital Paris, France $343M AUM

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return

OCWP

Owl Creek Wealth Partners Denver, Colorado $342M AUM

Torren Management San Diego, California $197M AUM

Farther Finance Advisors's VRDN Position: Q2 2026 in Review

Farther Finance Advisors reduced its Viridian Therapeutics (VRDN) stake by 72% in Q2 2026, selling an estimated $14.4K and leaving 338 shares worth $6.23K. The position accounts for ﹤0.01% of the portfolio, ranked #4674.

Farther Finance Advisors first reported a position in VRDN in Q4 2023 and has held it in 11 quarters since. The position peaked at $42.2K in Q4 2025. 12 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Farther Finance Advisors held 338 shares of Viridian Therapeutics worth $6.23K as of Q2 2026.
Farther Finance Advisors sold 891 Viridian Therapeutics shares in Q2 2026, an estimated $14.4K.
Viridian Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #4674 holding.
Farther Finance Advisors first reported a position in Viridian Therapeutics in Q4 2023 and has held it in 11 quarters since.
Farther Finance Advisors's Viridian Therapeutics position peaked at $42.2K in Q4 2025.
12 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.